<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:6a9cdaba-539b-4768-8d5e-c492b3a0428b,g:0f138a66-3c41-4a4d-a286-37b9255723ba,d:019d6cfc389c4cf3b1929a2eaede7f67--><html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mdxg-20210803</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N180L2ZyYWc6YjQ0MGNiNmQzN2QzNDY1MDhkNTRiZjJmZmUxMDE0YmEvdGFibGU6Y2E4Mzc5MWYyOGE3NGFiNWJmYTY1MzhkNzI2MGUxNmYvdGFibGVyYW5nZTpjYTgzNzkxZjI4YTc0YWI1YmZhNjUzOGQ3MjYwZTE2Zl8yLTEtMS0xLTA_edc3964c-9475-41d5-8ae7-dead79b9d7bd">0001376339</ix:nonNumeric><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N180L2ZyYWc6YjQ0MGNiNmQzN2QzNDY1MDhkNTRiZjJmZmUxMDE0YmEvdGFibGU6Y2E4Mzc5MWYyOGE3NGFiNWJmYTY1MzhkNzI2MGUxNmYvdGFibGVyYW5nZTpjYTgzNzkxZjI4YTc0YWI1YmZhNjUzOGQ3MjYwZTE2Zl80LTEtMS0xLTA_c49f3310-c943-45b0-8c87-3c3549b23b7e">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mdxg-20210803.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-03</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i019d6cfc389c4cf3b1929a2eaede7f67_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkx_73bb1c1b-e4de-4f5d-996a-5eb0c44d276c">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl8yNjY_010548d7-ba6e-48ce-ae41-21374672879f">August 3, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDky_7f572413-0523-48f3-ac5a-c4b2cbfbe926">MIMEDX GROUP, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTAtMS0xLTA_d5afe9d5-d07b-43c1-b5c0-75f032fdb24b">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTItMS0xLTA_e1fe21ae-48c9-4ba8-980d-4a5fe94199ff">001-35887</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTQtMS0xLTA_aac5f528-cc41-497b-86dc-a27c18e4ff45">26-2792552</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkz_a2c83742-9542-4cb0-a8d5-752cec542897">1775 West Oak Commons Ct., NE</ix:nonNumeric>, <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk0_f47252cc-cc85-49dd-8c13-e3c279a0c5d3">Marietta</ix:nonNumeric> <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk1_d91af8b0-dfd8-4403-8f66-8175854f754f">GA</ix:nonNumeric> <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk2_4950b0fa-5422-4845-875d-550248d22072">30062</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk3_a7df9d3f-8e34-40cb-9219-3bbff4c70848">770</ix:nonNumeric>) <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk4_2e765f91-7713-41fd-a74d-77c488d11e21">651-9100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:0.1%"></td><td style="width:2.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18wLTAtMS0xLTA_4821b00f-ddcc-40b7-a49d-d42678786f45">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18xLTAtMS0xLTA_e9ea04ae-6507-4eae-824c-cb0c12782014">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18yLTAtMS0xLTA_8ba905f4-ed73-47f5-bdd9-2f4fadd5a0a6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18zLTAtMS0xLTA_c4442e03-b4f0-4170-ba26-12a446b9192a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.350%"><tr><td style="width:1.0%"></td><td style="width:27.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTAtMS0xLTA_e9e2d84c-6f36-4dcc-803a-333acfc8d647">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTItMS0xLTA_aee54f97-3394-4b8a-ba97-b75896e37427">MDXG</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTQtMS0xLTA_56226558-229c-4708-a1df-ceb04b331dfa">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkw_f3aaabb2-0ec0-4851-a083-d56a682e01d4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Important Cautionary Statement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Important Cautionary Statement </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This report includes forward-looking statements. Statements regarding: (i) future sales or sales growth; (ii) the status, timing, and expected results of the Company&#8217;s clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission and eventual BLA approvals; (iii) the timing of our disclosure of clinical trial results; (iv) the results of future scientific studies; (v) expectations regarding our ability to sell EPIFIX in other countries, (vi) the effectiveness of amniotic tissue as a therapy for any particular indication or condition, and (vii) future increases in research and development spending. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," &#8220;goal,&#8221; &#8220;outlook,&#8221; "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors; (ii) the status, timing, and expected results of the Company&#8217;s clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission, depend on a number of factors including favorable trial results, patient access, and our ability to manufacture in accordance with CGMP and appropriate chemistry and manufacturing controls; (iii) the Company may change its plans due to unforeseen circumstances, or delays in analyzing and auditing results, and may delay or alter the timeline for future trials, analyses, or public announcements; (iv) the results of scientific research are uncertain and may have little or no value; (v) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (vi) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; and (vii) we may alter the timing and amount of planned expenditures for research and development based on the results of clinical trials and other regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this report and the Company assumes no obligation to update any forward-looking statement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02 Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, MiMedx Group Inc., (the &#8220;Company&#8221;) issued a press release (the &#8220;10-Q Press Release&#8221;) announcing the filing of its quarterly report on Form 10-Q for the period ended June 30, 2021. The 10-Q Press Release also includes certain information regarding the Company&#8217;s financial results for the period ended June 30, 2021. A copy of the 10-Q Press Release is attached hereto as Exhibit 99.1 and is incorporated herein for reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing information is furnished pursuant to Item 2.02, &#8220;Results of Operations and Financial Condition.&#8221; Consequently, it is not deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K. All information in the news release speaks as of the date thereof and the Registrant does not assume any obligation to update said information in the future. In addition, the Registrant disclaims any inference regarding the materiality of such information which otherwise may arise as a result of its furnishing such information under Item 2.02 of this report on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210803mdxg2q2021pressre.htm">Press Release </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210803mdxg2q2021pressre.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210803mdxg2q2021pressre.htm">ugust 3, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MIMEDX GROUP, INC.</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 3, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter M. Carlson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Carlson<br/>Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "mdxg-20210803.htm", "description": "8-K", "secsgml_size_bytes": 37418}]
{"company-data": {"conformed-name": "MIMEDX GROUP, INC.", "cik": "0001376339", "assigned-sic": "3841", "irs-number": "262792552", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35887", "film-number": "211141188"}, "business-address": {"street1": "1775 W OAK COMMONS COURT, NE", "city": "MARIETTA", "state": "GA", "zip": "30062", "phone": "(770) 651-9100"}, "mail-address": {"street1": "1775 W OAK COMMONS COURT, NE", "city": "MARIETTA", "state": "GA", "zip": "30062"}, "former-company": {"former-conformed-name": "Alynx, Co.", "date-changed": "20060922"}}
mdxg-20210803
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM
8-K
____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
August 3, 2021
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
Florida
001-35887
26-2792552
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
1775 West Oak Commons Ct., NE
,
Marietta
GA
30062
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (
770
)
651-9100
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.001 par value per share
MDXG
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Important Cautionary Statement
Important Cautionary Statement
This report includes forward-looking statements. Statements regarding: (i) future sales or sales growth; (ii) the status, timing, and expected results of the Company's clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission and eventual BLA approvals; (iii) the timing of our disclosure of clinical trial results; (iv) the results of future scientific studies; (v) expectations regarding our ability to sell EPIFIX in other countries, (vi) the effectiveness of amniotic tissue as a therapy for any particular indication or condition, and (vii) future increases in research and development spending. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "goal," "outlook," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations.
Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors; (ii) the status, timing, and expected results of the Company's clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission, depend on a number of factors including favorable trial results, patient access, and our ability to manufacture in accordance with CGMP and appropriate chemistry and manufacturing controls; (iii) the Company may change its plans due to unforeseen circumstances, or delays in analyzing and auditing results, and may delay or alter the timeline for future trials, analyses, or public announcements; (iv) the results of scientific research are uncertain and may have little or no value; (v) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (vi) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; and (vii) we may alter the timing and amount of planned expenditures for research and development based on the results of clinical trials and other regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this report and the Company assumes no obligation to update any forward-looking statement.
Item 2.02 Results of Operations and Financial Condition.
On August 3, 2021, MiMedx Group Inc., (the "Company") issued a press release (the "10-Q Press Release") announcing the filing of its quarterly report on Form 10-Q for the period ended June 30, 2021. The 10-Q Press Release also includes certain information regarding the Company's financial results for the period ended June 30, 2021. A copy of the 10-Q Press Release is attached hereto as Exhibit 99.1 and is incorporated herein for reference.
The foregoing information is furnished pursuant to Item 2.02, "Results of Operations and Financial Condition." Consequently, it is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K. All information in the news release speaks as of the date thereof and the Registrant does not assume any obligation to update said information in the future. In addition, the Registrant disclaims any inference regarding the materiality of such information which otherwise may arise as a result of its furnishing such information under Item 2.02 of this report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description of Exhibit
99.1
Press Release
A
ugust 3, 2021.
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MIMEDX GROUP, INC.
Date: August 3, 2021
By:
/s/ Peter M. Carlson
Peter M. Carlson
Chief Financial Officer